# Epsilon Molecular Engineering

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/epsilon-molecular-engineering

- Industry: Biotechnology
- Headquarters: Saitama, Japan
- Website: www.epsilon-mol.co.jp
- Total disclosed funding: $3.2M
- Latest round: Series A (Dec 24, 2020)
- Investors on record: 4

## About

Founded in 2016 and based in Saitama, Japan, Epsilon Molecular Engineering Inc. d.b.a Epsilon Molecular Engineering specializes in advanced biomolecular technologies, focusing on VHH antibodies for pharmaceutical and diagnostic applications. They provide innovative solutions to enhance drug development processesEpsilon Molecular Engineering Inc. develops VHH antibodies and has pivoted towards integrating proprietary cDNA display technology for product enhancements. In May 2026,Epsilon Molecular Engineering raised an undisclosed amount in venture funding from MIRAIDOOR and venture debt funding from Saitama Resona Bank and Japan Finance Corporation. Epsilon Molecular Engineering specializes in the development and application of advanced biomolecular technologies, particularly focusing on VHH antibodies. Their key offerings include the PharmaLogical® Library, a humanized VHH antibody library engineered through proprietary cDNA display technology. This innovative library is central to their high-throughput VHH screening and profiling service known as 'The Month,' which is designed to facilitate the rapid identification and optimization of VHH antibodies for various applications. These efforts primarily support the pharmaceutical, in vitro diagnostics, and research reagent sectors, addressing critical needs in drug development and diagnostic testing. The company serves a diverse clientele, including research institutions, biotech firms, and pharmaceutical companies, primarily targeting markets in North America, Europe, and Asia.Epsilon Molecular Engineering generates revenue through strategic partnerships and service agreements with its clients in the biomedical field. Transactions typically occur on a business-to-business (B2B) basis, where clients engage the company for specific projects or ongoing research collaborations, often leveraging the PharmaLogical® Library and the associated screening services. The revenue model is structured around contracts that specify deliverables, timelines, and milestones, ensuring transparent engagement with clients. Revenue is derived from project-based fees for customized VHH antibody development or licensing agreements related to their proprietary technologies, focusing on effective solutions for drug discovery and diagnostics. Epsilon Molecular Engineering plans to expand its product offerings and enter new markets using recent funding. The company plans to use May 2026 funding to expand into IgG monoclonal antibody screening and advance animal-free antibody production by integrating diverse biomolecules for applications in pharmaceuticals, diagnostics, and research.

## Funding rounds

- Series A, Dec 24, 2020, $1.1M — Kao Corporation, Mitsubishi UFJ Capital, Gungin Leasing
- Series A, Oct 23, 2019, $2.1M — Mitsubishi UFJ Capital, UntroD Capital

## Investors

- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series A
- UntroD Capital — Series A
- Kao Corporation — Series A
- Gungin Leasing (https://capitalatlas.ai/funds/gungin-leasing) — Series A